Spaulding Principal Investigator, Felipe Fregni, MD, PhD, MMSc, MPH, MEd, stated "We have seen great results with ESStim™ across the chronic pain and movement disorder indications.
This funding will enable RetiSpec to accelerate the commercialization of its groundbreaking technology aimed at early detection of Alzheimer's disease.
